|
|
|
|
E. coli PNP Publications Zhang Y, Parker WB, Sorscher EJ, Ealick SE (2005) PNP anticancer gene therapy. Current Topics in Medicinal Chemistry 5: 1259-1274. Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AEA, Silamkoti AV, Fowler AT, Waud WR, Secrist JA III (2005) Design and evaluation of 5’-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant. Nucleosides, Nucleotides, and Nucleic Acids 24: 387-392. Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR (2005) Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Hum Gene Ther. 16: 339-47. Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, and Sorscher EJ (2004) Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the Escherichia coli Purine Nucleoside Phosphorylase Gene. Cancer Res. 64: 6610-6615. Curlee KV, Parker WB, and Sorscher EJ (2004) Tumor sensitization to purine analogs by E. coli PNP Methods Mol. Med. 90: 223-246. Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, and Ealick SE (2003) Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem. Biol. 10: 1173-1181. Hassan AE, Parker WB, Allan PW, Montgomery JA, and Secrist JA 3rd. (2003) Selective metalation of 6-methylpurines: synthesis of 6-fluoromethylpurines and related nucleosides. Nucleosides Nucleotides Nucleic Acids 22: 747-749. Bennett EM, Li C, Allan PW, Parker WB, and Ealick SE (2003) Structural basis for substrate specificity of Escherichia coli purine nucleoside phosphorylase. J. Biol. Chem. 278: 47110-47118. Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, and Sorscher EJ (2003) A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 304: 1280-1284.Parker WB, Allan PW, Hassan AEA, Secrist JA III, Sorscher EJ, and Waud WR (2003) Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Esherichia coli purine nucleoside phosphorylase. Cancer Gene Therapy 10: 23-29. Appleby TC, Mathews II, Porcelli M, Caciapuoti G, and Ealick SE (2001) Three-dimensional structure of a hyperthermophilic 5'-deoxy-5'-methylthioadenosine phosphorylase from Sulfolobus solfataricus. J. Biol. Chem. 276: 39232-39242. Hassan AEA, Shortnacy-Fowler AT, Montgomery JA, and Secrist JA III (2000) A convenient synthesis of 2'-deoxy-2-fluoroadenosine; a potential prodrug for suicide gene therapy. Nucleosides, Nucleotides, and Nucleic Acids 19: 559-565. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, and Sorscher EJ (2000) In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of tumor cells. Gene Therapy 7: 1738-1743. Sorscher EJ, Bennett LL Jr, and Parker WB (January 25, 2000) Purine nucleoside phosphorylase gene therapy for human malignancy. US Patent number 6,017,896. Hassan AE, Abou-Elkair RA, Montgomery JA, and Secrist JA III (2000) Convenient syntheses of 6-methylpurine and related nucleosides. Nucleosides, Nucleotides, and Nucleic Acids 19:1123-1134. Secrist JA III, Parker WB, Allan PW, Bennett LL Jr, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, Gillespie GY, Gadi VK, and Sorscher EJ (1999). Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 18: 745-757. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, and Bennett LL Jr (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 55: 1673-1681. Mao C, Cook WJ, Zhou M, Federov A, Almo SC, and Ealick SE (1998) Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogs. Biochemistry 37: 7135-7146. Hughes BW, King SA, Allan PW, Parker WB, and Sorscher EJ (1998) Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J. Biol. Chem. 273: 2322-2328. Erion MD, Takabayashi K, Smith HB, Kessi J, Wagner S, Honger S, Shames S, and Ealick SE (1997) Purine nucleoside phosphorylase 1. Structure-function studies. Biochemistry 36: 11725-11734. Erion MD, Soeckler JD, Guida WC, Walter RL, and Ealick SE (1997) Purine nucleoside phosphorylase 2. Catalytic mechanism. Biochemistry, 36: 11735-11748. Stoeckler JD, Poirot AF, Smith RM, Parks RE Jr, Ealick SE, Takabayashi K, and Erion MD (1997) Purine nucleoside phosphorylase 3. Reversal of purine base specificity by site-directed mutagenesis. Biochemistry 36: 11749-11756. Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, and Sorscher EJ (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Human Gene Therapy 8: 1637-1644. Mao C, Cook WJ, Zhou M, Koszalka GW, Krenitsky TA, and Ealick SE (1997) The crystal structure of Escherichia coli purine nucleoside phosphorylase: A comparison with the human enzyme reveals a conserved topology. Structure 5: 1373-1383. Bebok Z, Abai A, Dong JY, Kirk K, Berta G, Hughes B, Kraft A, Burgess S, Shaw W, Felgner PL, and Sorscher EJ (1996) Efficiency of plasmid delivery and expression following lipid mediated gene transfer to human cells in vitro. J. Pharmacol. Exp. Therapeut. 279: 1462-1469. Sorscher EJ, Parker WB, and Bennett LL Jr (September 3, 1996) Purine nucleoside phosphorylase gene therapy for human malignancy. US Patent number 5,552,311. Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver RI Jr, Parker WB, and Sorscher EJ (1995) Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55: 3339-3345. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, and Parker WB (1994) Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Therapy 1: 233-238. Summary of E. coli PNP publications by other laboratories. Deharvengt S, Rejiba S, Wack S, Aprahamian M, Hajri A (2007)
Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the
bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int
J Oncol. 30: 1397-1406. Cai X, Zhou J, Lin J, Sun X, Xue X, Li C. (2005) Experimental studies on PNP suicide gene therapy of hepatoma. J Huazhong. Univ Sci Technolog Med Sci. 25:178-181. Arvidsson Y, Sumantran V, Watt F, Uramoto H, Funa K. (2005) Neuroblastoma-specific cytotoxicity mediated by the Mash1-promoter and E. coli purine nucleoside phosphorylase. Pediatr Blood Cancer. 44: 77-84. Heinkelein M, Hoffmann U, Lucke M, Imrich H, Muller JG, Meixensberger J, Westphahl M, Kretschmer A, Rethwilm A. (2005) Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors. Cancer Gene Ther. 12: 947-953 Asai T, Wims LA, Morrison SL. (2005) An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery. J Immunol Methods. 299: 63-76. Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL. (2005) A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng. 21: 145-155. Deharvengt S, Wack S, Aprahamian M, Hajri A. (2005) Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med. 7: 672-680. Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, Both GW, and Russell PJ (2004) Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 6: 1343-1357. Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW, and Russell PJ (2004) Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Therapy 11: 1559-1567. Critchley RJ, Jezzard S, Radford KJ, Goussard S, Lemoine NR, Grillot-Courvalin C, Vassaux G (2004) Potential therapeutic applications of recombinant, invasive E. coli. Gene Therapy 11: 1224-1233 Deharvengt S, Wack S, Uhring M, Aprahamian M, and Hajri A (2004) Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside. Pancreas 28: E54-64. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM, Wang XY, Both GW, and Russell PJ (2004) Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J. Gene Med. 6: 43-54. Messina M, Yu DM, Both GW, Molloy PL, Robinson BG (2003) Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells. J Clin Endocrinol Metab 88: 1310-1318. Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW, and Russell PJ (2002) Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Therapy 9: 759-768. Martiniello-Wilks R, Tsatralis T, Russell P, Brookes DE, Zandvliet D, Lockett LJ, Both GW, Molloy PL, and Russell PJ (2002) Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Therapy 9: 443-452. Krohne TU, Shankara S, Geissler M, Roberts BL, Wands JR, Blum HE, and Mohr L (2001) Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34: 511-518. Bzowska A, Kulikowska E, and Shugar D (2000) Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol. Ther. 88: 349-425. Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, Blum HE, and Wands JR (2000) Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 31: 606-614. Both GW (2000) Nucleic Acid delivery with ovine adenoviral vectors. US patent number 6,020,172. Park BJ, Brown CK, Hu Y, Alexander HR, Horti J, Raje S, Figg WD, and Bartlett DL (1999) Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Human Gene Therapy 10: 889-898. Puhlmann M, Gnant M, Brown CK, Alexander HR, and Bartlett DL (1999) Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Human Gene Therapy 10: 649-657. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ, and Russell PJ (1998) In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Human Gene Therapy 9: 1617-1626. Both GW (1997) Gene Therapy using ovine adenoviral vectors. International publication number WO 97/06826. Lockett L J, Molloy PL, Russell PJ, and Both GW (1997) Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer. Res. 3: 2075-2080. Nestler U, Heinkelein M, Lucke M, Meixensberger J, Scheurlen W, Kretschmer A, and Rethwilm A (1997) Foamy virus vectors for suicide gene therapy. Gene Therapy 4: 1270-1277. Fathi R, Nawoschik KJ, Zavoda M, and Cook AF (1997) Enzymatic synthesis of 2'5'-dideoxy purine nucleosides and related compounds. Nucleosides and Nucleotides 16: 1907-1920. Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW, and Vogelstein B (1996) Converting cancer genes into killer genes. Proc. Natl. Acad. Sci. USA 93: 4192-4196. Anderson-McKay JE, Both GW, and Simpson GW (1996) Stereoselective synthesis of 6-methyl-9-(2-deoxy-ß-D-erythro-pentofuranosyl)purine. Nucleosides and Nucleotides 15: 1307-1313. |
|
Send mail to our
webmaster with questions or comments about this web site.
Legal Information. |